Evidence map›Paper›PMID 42295550›Full record

ArticleOncology and therapy2026

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Giandomenico Roviello, Mattia Alberto Di Civita, Daniele Santini, Elisabetta Gambale, Lidia Strigari, Simone Scagnoli, Laura Pappalardo, Andrea Torchia, Andrea Botticelli, Serena Pillozzi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it.
Mattia Alberto Di CivitaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Daniele SantiniDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Elisabetta GambaleDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lidia StrigariDepartment of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Simone ScagnoliDepartment Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Laura PappalardoDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.
Andrea TorchiaDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Andrea BotticelliDepartment Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Serena PillozziDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPolypharmacy is common in patients with advanced urothelial carcinoma (UC) receiving avelumab maintenance therapy, raising concerns about potential drug-drug interactions (DDIs).

methodsWe retrospectively analyzed patients enrolled in the multicenter MALVA study treated with avelumab maintenance. Concomitant medications were assessed using the Drug Interaction and Pharmacogenomics Information Network (Drug-PIN®). Drug-PIN® scores were calculated with and without avelumab and correlated with overall survival (OS) and progression-free survival (PFS).

resultsAmong 115 patients, Drug-PIN® scores showed wide inter-patient variability but were not significantly influenced by inclusion of avelumab. No significant differences in OS or PFS were observed across Drug-PIN® risk categories.

conclusionIn this real-world cohort, polypharmacy and Drug-PIN® score did not impact survival outcomes, suggesting that, within the limitations of this exploratory analysis, Drug-PIN®-assessed DDI burden was not associated with survival outcomes in patients receiving avelumab maintenance therapy.

Indexed as

AvelumabDrug–drug interactionsDrug-PIN®Maintenance immunotherapyPolypharmacyUrothelial carcinoma

Identifiers

PMID42295550
PMCPMC13575059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.